Biohaven Shares Surge as New Drugs Deliver Breakthrough Results in Graves’ Disease and IgA Nephropathy
Biohaven shares rose after strong early results from 2 drugs that quickly lower harmful antibodies in autoimmune diseases.
NOTRELOAD AI
Japan Grants Orphan Drug Designation to Vanda’s Imsidolimab for Rare Skin Disease GPP
Vanda’s drug imsidolimab receives orphan drug status in Japan for the rare skin disease GPP, speeding up approval.
IREN Targets $4.4 Billion ARR with $1.6B Blackwell GPU Deal at Childress
IREN signs $1.6B Dell deal for AI hardware, boosting revenue target to $4.4B as it expands data centers by 2027.
FDA Review Back on Track – Corcept Resubmits Relacorilant for Cushing’s Treatment
Corcept will resubmit its NDA for relacorilant to treat Cushing’s syndrome after positive FDA feedback.
American Cancer Society Adds Easy Shield Blood Test to Colon Cancer Screening Guidelines
New blood test added to cancer screening guidelines makes it easier to check for colorectal cancer, helping more people get tested early.
FDA Fast-Tracks First-Ever Treatment for Rare Muscle Disease LGMD2I/R9
BridgeBio’s BBP-418 receives FDA Priority Review with a November 27, 2026 PDUFA date. If approved, it would be the first therapy for LGMD2I/R9 and any form of limb-girdle muscular dystrophy.